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www.co-lipidology.coma a a,bEsther Smeets , Svenja Meiler , and Esther LutgensPurpose of review
The role of lymphocytes in the chronic inflammatory disease atherosclerosis has emerged over the past
decade. Co-stimulatory molecules of the heterogeneous tumor necrosis factor receptor superfamily play a
pivotal role in lymphocyte activation, proliferation and differentiation. Here we describe the immune
modulatory properties and mechanisms of four tumor necrosis factor receptor superfamily members in
atherosclerosis.
Recent findings
CD40/CD40L, OX40L/OX40, CD70/CD27 and CD137/CD137L are present in human atherosclerotic
plaques and have shown strong immune modulatory functions in atherosclerosis, resulting in either
atherogenic or atheroprotective effects in mouse models of atherosclerosis.
Summary
Insight into the immune modulatory mechanisms of co-stimulatory interactions in atherosclerosis can
contribute to clinical exploitation of these interactions in the treatment of cardiovascular disease.
Keywords
adaptive immune system, atherosclerosis, co-stimulatory molecules, lymphocytes, tumor necrosis factor receptor
superfamilyINTRODUCTION the aortic root and adoptive transfer of CD4þ T cellsAtherosclerosis is a chronic inflammatory disease of
the arterial wall. Injurious stimuli including shear
stress and modification of LDL and its subendothelial
deposition activate the endothelium [1,2
&&
]. Sub-
sequently, inflammatory cells of both the innate
and adaptive immune system are attracted and
infiltrate into the subendothelial space where athero-
sclerotic plaques arise via intertwined immunologi-
cal interactions between immune cells, endothelial
cells, platelets and smooth muscle cells [3
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The role of the innate immune system in atheroscle-
rosis has long been established. In the early 1990s,
the contribution of the adaptive immune system
was considered as T-lymphocytes and anitgen pre-
senting cells (APCs) were found in close proximity
within the atherosclerotic plaque [1,2
&&
]. Studies in
animal models indeed proved lymphocytes to play a
major role in atherosclerosis. For example, Cd4/
Apoe/ mice show less atherosclerotic plaques iniams & Wilkins. Unauthointo atherosclerosis-prone SCID Apoe/mice aggra-
vates atherogenesis in an interferon (IFN)g-associ-
ated manner [4,5]. T lymphocytes recognize
epitopes on the apoB100 unit of native LDL, which
supports the production of IgG to oxLDL by B cells
[6]. Lymphocytes are also present in aortic tertiary
lymphoid organs in very advanced atherosclerosis,
in which they are considered to serve as a site for
local responses against plaque antigens [7].
The divergent effects of B cells on athero-
sclerosis are attributed to subset-specific effects.
B1a B cells, mainly present in peritoneal cavities,rized reproduction of this article is prohibited.
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KEY POINTS
 The adaptive immune systems impacts atherogenesis.
 TNFRSF family of co-stimulators regulates immune cell
activation in the context dependent manner.
 Various members of the TNFRSF family are known
atherogenic or atheroprotective factors.
 Targeting TNFRSF members may enable specific
immunomodulation in atherosclerosis.
Lymphocytic TNFSF co-stimulators in atherogenesis Smeets et al.secrete atheroprotective natural IgM antibodies
against oxidation-specific epitopes of LDL, thereby
preventing oxLDL uptake by macrophages via their
scavenger receptors and their subsequent activation
[8,9]. Conventional B2 B cells undergo isotype
switching and as such are capable of secreting differ-
ent immunoglobulin isotypes in addition to IgM. B2
B cells have been shown atherogenic by studies
using depleting monoclonal CD20-antibodies or
adoptive transfer of B2 B cells in Apoe/ and
Ldlr/ mice [10,11]. Association between B2 B cell
secreted IgG and atherosclerosis has been proposed
by some, but not all, articles, as well as B2 B cell-
induced T cell activation either through antigen
presentation or cytokine secretion [12–14].
Co-stimulatory molecules tightly regulate the
interactions among T cells, B cells and dendritic
cells and their subsequent immune cell activation
or modulation. Three signals are required for acti-
vation of naı̈ve T or B cells (and other APCs such as
dendritic cells and macrophages): the first signal is
the binding of the T-cell receptor (TCR) or B-cell
receptor (BCR) to an antigen, the second signal is
provided through co-stimulatory molecules and the
third signal through cytokines secreted by cells car-
rying the co-stimulatory molecules [15].
The engagement of co-stimulatory molecules on
the surface of mature APCs to their counter recep-
tors on T cells is required for proliferation and escape
from anergy. Primed T cells are a heterogeneous
group of cells differentiated into one of the T-cell
subsets based on encountered APC-secreted cyto-
kine profile: T-helper CD4þ (with TH1, TH2, TH17
subprofiles), cytotoxic CD8þ cells and regulatory
T cells [16].
Although the effects of the different co-stimu-
latory molecules are well established, the role of the
different co-stimulatory pathways during the patho-
genesis of atherosclerosis still needs to be fully elu-
cidated. In this review, we will summarize the role of
the tumor necrosis factor receptor superfamily
(TNFRSF) members in atherosclerosis, and highlight
the most important findings.Copyright © Lippincott Williams & Wilkins. Unau
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SUPERFAMILY
In atherosclerosis, several members of the TNF
(receptor) superfamily (such as CD40, Ox40,
CD137, GITR, CD30, TNF-related apoptosis-induc-
ing ligand and CD27) have been studied in the





,37–41]. In general, the expression
of these molecules is enhanced upon engagement of
an antigen with the TCR or BCR.
Most TNFRSF members lack intrinsic activity and
require downstream adaptor proteins to induce intra-
cellular signaling, TNFR-associated factors (TRAFs).
TRAFs are recruited to the cytoplasmic tail of the
trimeric TNFRs and engage with the conserved TRAF
domain [41]. Until today, seven distinct TRAF mol-
ecules have been identified that interact with
TNFRSF, of which five are implicated in atherosclero-
sis in various cellular environments: TRAF1, 2, 3, 5
and 6 [42]. Depending on cell type, environmental
conditions and TRAF-binding site different down-
stream signaling pathways are initiated [43].
Several studies have revealed the effects of
the different TRAF molecules in atherosclerosis,
but the role of the different individual TNFRSF–
TRAF interactions is still under investigation.
Endothelial specific Traf6//Apoe/ mice showed
reduced atherosclerosis, whereas myeloid cell-
specific TRAF6-deficient Apoe/ mice developed
accelerated atherosclerosis [44]. Traf1//Ldlr/
mice developed smaller atherosclerotic lesions
because of impaired monocyte migration and
adhesion to the endothelium [45
&&
]. TRAF5 is
atheroprotective, as shown by Traf5//Ldlr/ mice
[46]. TRAF3 serves as an inhibitor for TRAF2/5 nuclear
factor (NF)kB activation upon stimulation of various
TNFRSF members [47]. TRAF2 and TRAF3 upregula-
tion is associated with shear stress [48,49].
The most dominant outcome of TNFRSF-TRAF
signaling is NFkB and mitogen-activated protein
kinase (MAPK) activity, which mediates activation,
proliferation and the production of proinflamma-
tory cytokines and adhesion molecules [41,42].
In this review, we will discuss the contribution
of CD40/CD40L, OX40/OX40L, CD27/CD70 and
CD137/CD137L to atherogenesis in detail, as these
TNFRSF members are well studied and are considered
promising candidates for therapy in atherosclerosis.CD40/CD40L
The CD40/CD40L axis is one of the best-studied co-
stimulatory pathways. CD40L, also known as CD154
or TNFSF5, is expressed on various cell types, both
immune cells and nonhematopoietic cells, particu-
larly CD4þ T cells and platelets [21]. CD40-CD40Lthorized reproduction of this article is prohibited.
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Table 1. TNFRSF in human and mouse atherosclerosis
Ligand Receptor Mouse Human
CD40L CD40 Atherogenic – shown by administration
of neutralizing antibodies to CD40L,
Cd40l genetically deficient mice,
Cd40/ mice [18–21]
Expression of CD40(L) in atherosclerotic
lesion [22]
Increased levels of sCD40L in patients with
unstable angina [23]
Polymorphisms in CD40 gene correlate with
unstable coronary plaques and risk of
coronary plaque disruption [24]
CD137L CD137 Atherogenic – shown by administration
of agonistic antibody against CD137L
and Cd137 genetically deficient mice
[23,25]
Expression of CD137 in atherosclerotic
lesion [25]
Increased sCD137 levels in patients with
ACS [26,27]
CD70 CD27 Atherogenic – shown by reduced
atherosclerosis in Cd70 Apoe
transgenic mice [28]
Expression of CD70 and CD27 on T cells in
atherosclerotic lesions [29]
OX40L OX40 Atherogenic – shown by administration
of neutralizing antibodies to OX40
and Ox40l genetically deficient mice
[30,31,32]
Increased expression of OX40 in patients
with unstable angina
Increased sOX40 levels in patients with
unstable angina [33]
Polymorphisms in TNFSF4 gene correlate
with myocardial infarction in women [30]
GITRL GITR Uncertain Expression of GITR(L) in atherosclerotic pla-
que intima [34]
Decreased number of GITRþ Treg cells in
atherosclerotic lesions [35]
CD30L CD30 Atherogenic – shown by administration
of CD30L-antibody [36&&]
Inconclusive [37]
TRAIL TRAILR Atheroprotective – shown in
Trail-deficient mice [38,39]
Expressed in human atherosclerotic
plaque and lower sTRAIL levels in coron-
ary disease patients [40,41]
ACS, acute coronary syndrome; GITR, glucocorticoid-induced TNFR-related protein; sTRAIL, soluble TRAIL; TNFRSF, tumor necrosis factor receptor superfamily;
TNFSF, tumor necrosis factor superfamily; TRAIL, TNF-related apoptosis-inducing ligand; TRAILR, TRAIL receptor.
Special commentaryinteractions mediate T-cell activation, proliferation
and cytokine secretion required for B-cell activation.
CD40 is constitutively expressed on APCs, including
dendritic cells and B cells on which its expression is
required for humoral immune responses such as
proliferation and isotype switching [16,50]. CD40
has two distinct binding sites for TRAF: a proximal
site for TRAF1/2/3/5 and a distal site for TRAF6 bind-
ing [51]. TRAF6 activation is linked to NFkB, Signal
Transducer and Activators of Transcription 3 and
protein kinase B activation [52]. TRAF1/2/3/5 acti-
vates the NFkB, MAPK/p38 and c-Jun N-terminal
kinases (JNK) pathways [43].
It is important to recall that CD40/CD40L is
expressed on numerous plaque-related cells, such
as macrophages, platelets and dendritic cells, in
addition to lymphocytes. Various studies showedopyright © Lippincott Williams & Wilkins. Unautho
520 www.co-lipidology.comthat Apoe//Cd40l/ mice, as well as anti-CD40L
antibody-treated Ldlr/ or Apoe/ develop reduced
atherosclerosis and/or a plaque phenotype that
shows a reduction in inflammation, reminiscent of
stable atherosclerotic plaques in humans [18–30].
The effect of CD40L on atherosclerosis appeared
hematopoietic cell-independent, as shown by
Cd40l//Ldlr/ chimeras. No difference regarding
plaque size and phenotype was observed in these
mice [53]. However, the contribution of the different
CD40L-expressing hematopoietic cell-types still
needs to be confirmed using conditional knock-out
mice. Platelet CD40L is atherogenic, and plays a
major role in platelet-leukocyte aggregation and leu-
kocyte recruitment to the endothelium [16].
Cd40//Apoe/mice, as well as Cd40//Ldlr/
chimeras show reduced atherosclerosis and developrized reproduction of this article is prohibited.
Volume 24  Number 6  December 2013
Lymphocytic TNFSF co-stimulators in atherogenesis Smeets et al.atherosclerotic plaques that contain less inflamma-
tory cells and more fibrosis [54]. In contrast, in
another report, Cd40//Ldlr/ mice fed with a
high-cholesterol diet for 8 and 16 weeks develop
atherosclerotic lesions comparable in size with
Ldlr/ mice [55]. The main pathway mediating
the proatherogenic role of CD40 in atherosclerosis
is the major histocompatibility complex (MHC)II-
related CD40-TRAF6 pathway. Mice with deficient
CD40-TRAF6 signaling in MHCIIþ cells developed
little atherosclerosis, owing to reduced leukocyte
recruitment and polarization towards Ly6Clow
monocytes and M2 macrophages. In contrast, mice
with deficient CD40-TRAF2/3/5 signaling in
MHCIIþ cells showed no reduction in atherosclero-
sis [54].
Polymorphisms in the CD40 gene (-1C/T) cor-
relate with unstable coronary plaques, whereas the
C allele frequency increased risk of coronary plaque
disruption in 699 patients [24]. Moreover, several
studies showed that sCD40L in the circulation
is highly correlated with cardiovascular risk in
humans, but its biological function remains to be
elucidated until today [23,56,57].CD27/CD70
CD27/TNFRSF7 is constitutively expressed on T cells
and its expression increases upon cell activation.
CD27 has also been identified on B cells, hemato-
poietic progenitors and natural killer cells. CD27
ligand, known as CD70 or TNFSF7, is transiently
expressed on activated T cells, activated B cells and
dendritic cells. The downstream signaling of CD27 is
mediated by TRAF2 and TRAF5, activating the NFkB
and JNK signaling pathways; CD70 ligation triggers
PI3K/Akt and MEK/extracellular-signal-regulated
kinases (ERK)/MAPK activation [17
&
,58].
Ligation of T cell CD27 to B cell CD70 has a
bidirectional effect. On the one hand, it increases
long-lasting T-cell survival in both primary and
memory responses, and the expansion of TH1
IFNg-secreting effector T cells [17
&
,59]. On the other
hand, CD70 triggering on B cells impairs the for-
mation of IgG antibodies, but not of IgM [17
&
]. CD27
ligation on B cells promotes cell proliferation and
cell cycle entry [60]. It is further upregulated during
germinal centre formation but does not elevate iso-
type switching to atherogenic IgG [60]. In addition,
CD27 on B cells ligates to CD70 on T cells to stimu-
late CD8þ T cells proliferation [61]. The complex
interactions indicate a fine balance between CD27
and CD70 expression on B and T cells for optimal
immune responses. CD27/CD70 rescues atheropro-
tective regulatory Foxp3þ T cells from apoptosis in
the thymus [62,63
&&
]. Moreover, antiatherogenicCopyright © Lippincott Williams & Wilkins. Unau
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in the thymus by CD27/CD70 [64
&&
]. The co-stimu-
latory molecules promote inflammation by impair-
ment of the development of TH17 helper T cells,
partly via JNK pathway activation by CD27.
van Olffen et al. recently showed that B cell-
specific Cd70-transgenic mice were protected against
atherosclerotic lesion development despite the
increase in IFNg producing effector T-cells. However,
this transgenic model exhibits B-cell loss and exhaus-
tion of the naı̈ve T-cell pool, and in atherosclerosis,
develops massive monocytosis. The authors explain
the observed phenotype by the increased suscepti-
bility of monocytes from CD70-transgenic mice to
apoptosis [28]. CD27 and CD70 have also been iden-
tified on lymphocytes in human plaques, suggesting
a role in atherogenesis [29].OX40/OX40L
OX40, also known as CD134 and TNFRSF4, is tran-
siently upregulated on activated CD4þ T cells, CD8þ
T cells and memory T cells, and plays a role in
sustained clonal expansion, cytokine secretion by
effector T cells and homeostasis of effector and
memory T cells [17
&
]. OX40 on regulatory T cells
either directly inhibits their suppressive capacity or
desensitizes effector T cells to the regulatory signal
[65
&&
]. As is true for many co-stimulatory molecules,
expression of OX40 is not restricted to lymphocytes,
but is also present on other cells. OX40 engages with
OX40L on plaque-related cells such as mature APCs,
smooth muscle cells and activated endothelial cells.
OX40L can be expressed on activated T cells simul-
taneous with OX40, creating an amplification of the
effector T cell responses. The intracellular signaling
upon OX40 ligation has been partly elucidated in
CD4þ T cells [17
&
]. Antigen recognition-independ-
ent activation depends on TRAF1, 2, 3 and 5-medi-
ated IkBa degradation, and subsequent NFkB1
activation, hence migration of transcription factors
p50 and RelA to the nucleus where it delivers signals
for survival, proliferation and cytokine secretion,
through NFATc1 activation [33,66]. Antigen recog-
nition-independent activation is triggered by B cells
and activated T cells. Moreover, in the antigen and
TCR-dependent pathway, OX40 activates a syner-
gizing pathway involving Akt [67].
Mice with mutation of the Ox40l gene devel-
oped smaller atherosclerotic lesions compared
with control animals, whereas mice overexpressing
the gene develop larger lesions, indicating an athe-
rogenic role for OX40L [30]. Nakano et al. [31]
recently demonstrated that Apoe//Ox40l/ mice
show reduced aortic atheroma compared with
Apoe/ mice because of OX40/OX40L-dependentthorized reproduction of this article is prohibited.
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Special commentaryneovascularization in vasa vasorum. Moreover,
similar to CD40L, the importance of vascular rather
than bone marrow OX40L is shown by transplan-
tation of Ox40l/ and wild-type bone marrow into
Apoe/mice [31]. Ldlr/mice treated with an anti-
OX40L antibody developed reduced atherosclerotic
lesions because of inhibition of the interleukin-4-
dependent TH2 switch. Consequently, the levels of
the atherogenic IgG1 immunoglobulin decreased,
whereas those of atheroprotective oxLDL IgM titers
increased. The authors found an increased interleu-
kin-5 concentration in the serum, which is associ-
ated with IgM secretion by B1 cells rather than B2
cells [68].
The effect of the OX40/OX40L axis is further
supported by the observation that patients with
unstable angina showed increased OX40 expression
on peripheral CD4þ T cells and increased soluble
OX40 concentration in their circulation [33]. The
rs3850641 allele of single-nucleotide polymorphism
in the TNFSF4 gene is associated with the risk of
myocardial infarction in women. In addition, three
haplotypes of the gene are more frequent in patients
with coronary artery disease [30].CD137/CD137L
CD137/TNFRSF9/4–1BB is expressed on activated
T cells, mainly CD4þ, as well as dendritic cells,
natural killer cells and granulocytes. Its ligand,
CD137L/TNFSF9, is constitutively expressed on B
cells and dendritic cells. Ligation of CD137 and
CD137L promotes T-cell expansion and proinflam-
matory cytokine secretion through TRAF1 and
TRAF2 recruitment and downstream NFkB and
ERK signaling [21,69,70].
CD137-deficient mice showed a reduction in
atherosclerotic lesions because of a downregulation
of proinflammatory cytokines, including IFNg, and
activation of monocytes/macrophages [71]. Similar
to CD40/CD40L, the widespread expression of
CD137/CD137L on various plaque-related cells,
such as endothelial and smooth muscle cells, com-
plicates the study of lymphocyte-specific athero-
genic effects. However, data suggest a role for this
T cell co-stimulator in atherogenesis, especially on
CD8þ T cells. The strongest evidence is provided by a
study from Olofsson et al. in which a CD137-agonist
was administered to Apoe/ mice. The atheroscler-
otic plaque size was only slightly larger in treated
mice. The plaque phenotype, however, changed
significantly and demonstrated an infiltration of
CD8þ T cells into aortic lesion as well as increased
expression of MHCII molecules. In the same study,
the presence of CD137 was confirmed on T cells and
endothelial cells in human atherosclerotic plaques.opyright © Lippincott Williams & Wilkins. Unautho
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bind the endothelial cells resulting in endothelial
cell activation and responses contributing to plaque
aggravation [25]. Recently, Cd137/ knockout mice
were found to develop reduced lesion sizes, initially
because of decreased IFNg production by T cells.
Moreover, CD137 induces the expression of TNFa,
a cytokine associated with the infiltration of leuko-
cytes into the subendothelial space and therefore
progression of atherosclerosis [71]. Studies to
acute coronary syndrome patients showed elevated
soluble CD137 levels in their circulation, as wells as
an increased expression of CD137 on peripheral
monocytes [26,27].FUTURE PERSPECTIVES
Besides lipid lowering, the importance of immune
responses in atherosclerosis has emerged. The
pivotal role of TNFRSF members in activation, differ-
entiation and function of immune cells including
lymphocytes allow modulation of the immune sys-
tem in a highly refined manner. Targeting co-stimu-
latory molecules of the TNFRSF in atherosclerosis
therefore will enable specific immune modulation
of immune cells rather than commonly used
systemic therapies, such as statins, b-blockers and
lipid-lowering drugs. However, exact mechanisms
of TNFRSF are still being unravelled.
So far, studies in humans and animal models
confirm the immune modulatory role for several
TNFRSF members in atherogenesis. Especially
CD40/CD40L, OX40/OX40L, CD27/CD70 and
CD137/CD137L interactions have been studied as
potential targets for immune modulation in vascu-
lar disease. Interestingly, each co-stimulatory dyad
modulates the immune system during atherogenesis
in its own way. CD40/CD40L predominantly affects
macrophage and T cell recruitment, activation and
polarization, with the CD40-TRAF6 pathway as
the dominant pathway in atherosclerosis. OX40
augments TH2-mediated isotype switching, result-
ing in increased IgG1 and decreased IgM antibodies
against oxLDL in hyperlipidemic conditions. The
CD27/CD70 axis fine-tunes the optimal B and T-cell
responses, and affects T helper cell development,
whereas CD137 activation results in increased CD8þ
cell infiltration in atherosclerotic plaques.
On the contrary, many key issues remain to be
elucidated. In which stage of the disease the indi-
vidual TNF(R)SF members exert their function, and
how they interact with another, is not clear. The
widespread expression of TNFRSF members beyond
lymphocytes complicates clarification of the cell-
type-specific TNFRSF members and their inter-
cellular interactions in atherosclerosis. Studies inrized reproduction of this article is prohibited.
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are therefore eagerly awaited. Moreover, down-
stream signaling pathways have not been fully elu-
cidated. Initial data regarding CD40-TRAF signaling
have shown that signaling pathways are highly
dependent on cell type and type of disease.
On the contrary, once the cell and disease-type
specific (inter)actions of the different TNFRSF mem-
bers have been unravelled, and their signaling path-
ways have been elucidated, therapeutic applications
in atherosclerosis will be feasible and have a high
possibility of being successful. In addition, TNFRSF
can be utilized as reliable biomarkers for risk esti-
mation of cardiovascular events, as soluble factors
correlate with cardiovascular risk.CONCLUSION
In this review, we have described the diverse actions
of the different co-stimulatory molecules in athero-
sclerosis. Co-stimulatory molecules have a great
potential to become therapeutic targets to treat or
halt the progression of cardiovascular diseases, as
they are strong modulators of the immune system, a
key feature they also show in atherosclerosis. By
mediating the immune system toward a modulatory
function by either blocking complete or cell-type
specific co-stimulatory pathways, or signaling inter-
mediates in the co-stimulatory pathways, athero-
sclerosis development or its progression could be
halted. However, caution must be applied to prevent
immunosuppressive complications.Acknowledgements
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